within Pharmacolibrary.Drugs.ATC.R;

model R05CB08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Domiodol is a mucolytic agent that was once used to treat respiratory disorders involving excessive or thick mucus, such as chronic bronchitis and other chronic obstructive pulmonary diseases. It is an expectorant formerly marketed in several countries but is not widely in medical use today and is not approved in most regions currently.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies for domiodol were found. The following estimates are based on general properties for mucolytic drugs of similar structure, administered orally to healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05CB08;
